Graham Sanders’ Post

🔬Debiopharm, an independent biopharmaceutical leader, is collaborating with ThinkingNode Life Science, Inc., a trailblazer in AI-powered drug discovery, to revolutionize cancer drug development with AI. 💡This partnership promises to enhance healthcare by: - Expanding drug indications by identifying new applications to benefit more patients. - Optimizing combination therapies for greater efficacy. - Validating mechanisms of action for targeted treatments. Conducting comparative analyses for optimal drug selection and development. 🎯The impact? Improved patient outcomes, a global advancement in cancer treatment, and a leap forward in healthcare innovation. Bertrand Ducrey, CEO of Debiopharm, calls it a "significant leap forward in cancer drug development." 🔄 What possibilities do you see in the integration of AI in cancer care and healthcare as a whole? Share your thoughts below ⬇️ #cancercare #cancertreatment #healthcareinnovation #healthcaremanagement #oncology Source: https://lnkd.in/g5pK9Fiy Disclaimer: Synthesised content in posts is purely my own and based on outside-in analysis of public data sources; it does not endorse nor reflect views of any current or past institutional affiliations

It’s been March Madness in the biotech industry this month with 8 VC rounds north of $130M. Here they are 👇 Mirador Therapeutics Precision medicine for immune-mediated inflammatory and fibrotic diseases Amount Raised: $400 million (Series A) Alumis Oral therapies to combat immune-mediated diseases Amount Raised: $259 million (Series C) Capstan Therapeutics Ttargeted in vivo RNA-based therapies Amount Raised: $175 million (Series B) Sionna Therapeutics Small molecule therapies for cystic fibrosis (CF) Amount Raised: $182 million (Series C) Clasp Therapeutics Innovating T-cell engagers for immuno-oncology. Amount Raised: $150 million (Series A) Engrail Therapeutics Transformational therapies to patients with devastating disorders of the nervous system Amount Raised: $157 million (Series B) FogPharma Drugs to address the limitations of today’s precision medicines and achieve universal druggability. Amount Raised: $145 million (Series E) Tubulis GmbH Uniquely matched antibody-drug conjugates (ADCs)  Amount Raised: $138.8 million (Series B2) Credit: Fierce Biotech fundraising tracker

Latest Life Science News / Updates : 📌 Regeneron is committing up to $500 million over the next five years for its new private financing arm. 📌 Clario has purchased ArtiQ, an artificial intelligence software developer that creates AI solutions for diagnosing and treating patients with respiratory disease. 📌 Genmab announces acquisition of ProfoundBio for $1.8 billion 📌 Obsidian Therapeutics has raised $160 million in a series C. 📌 Alterome Therapeutics, Inc Therapeutics has closed a $132 million series B, cash that will go toward the development of next-gen, small molecule targeted oncology therapies. 📌 Diagonal Therapeutics has raised $128 million to advance its antibody agonist-building platform. 📌 Boundless Bio is bringing in $100 million from its IPO as the precision oncology company becomes the latest biotech to go public in 2024. 📌 Lonza have appointed new CEO - Wolfgang Wienand

𝐅𝐨𝐠𝐏𝐡𝐚𝐫𝐦𝐚 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 $𝟏𝟒𝟓𝐌 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 𝐟𝐨𝐫 𝐅𝐎𝐆-𝟎𝟎𝟏 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 FogPharma FogPharma, a biopharmaceutical company focused on innovative therapies using its Helicon peptide platform, has closed a $145 million Series E financing round led by Nextech Invest Nextech Invest and other investors including RA Capital Management RA Capital Management and General Catalyst General Catalyst. The funding will support the clinical development of FOG-001, an intracellular TCF-blocking β-catenin inhibitor for solid tumors, and accelerate its discovery programs. FOG-001 targets the Wnt/β-catenin pathway, prevalent in colorectal cancer. The financing aims to address this unmet need and advance other disease targets. Mathai Mammen Mathai Mammen, M.D., Ph.D., FogPharma’s CEO, expressed confidence in FOG-001’s potential to impact cancer treatment and the company’s commitment to innovation. FogPharma's Helicon platform enables discovery of novel programs by modulating intracellular interactions. Nextech's Thilo Schroeder praised the company's progress. The financing follows FogPharma's growth in leadership and expertise, positioning it for further success in clinical and commercial endeavors. #InvestmentInHealth #DrugDiscovery #HeliconPlatform #PrecisionMedicine #funding #financing

Only a few days left to register for the 9th CAR-TCR Summit at the best rate! In case you haven't seen it yet, full agenda here: https://ter.li/eugziv This remains the industry's favorite meeting for CAR-T and TCR-based drug development, where you'll hear brand new insights from key academics, innovative biotechs and big-player pharma. We asked the industry what hot topics should be up for discussion this year - and you have spoken! So, in 2024, you'll join conversations on: 💢 Autoimmune applications of cell therapy, with advice from Cabaletta Bio & Adicet Bio, Inc 💢 How to innovate and accelerate your manufacturing processes with first-hand learnings from Gracell Biotechnologies, Kyverna Therapeutics, Takeda, Bristol Myers Squibb & Verismo Therapeutics 💢 How to improve efficacy in solid tumors with insights from Affini-T Therapeutics, Inceptor Bio, Obsidian Therapeutics & Memorial Sloan Kettering Cancer Center 💢 Advice and insights from investors including Vida Ventures, LLC, Sofinnova Partners & Northpond Ventures, plus how to secure cash runways with experienced players like Daiichi Sankyo US, Bristol Myers Squibb & Takeda Full details in the agenda here: https://ter.li/eugziv This is also your biggest networking opportunity of the year as 1,000+ cell therapy experts come together to collaborate, build professional networks and socialize with new and old friends. Don't be the only one to miss it! Best value tickets are available now. Access your saving here: https://ter.li/d87kfc Isabella Maxton Jade Wallace Elly Kanaan Kiran Thomson Luke O'Neill Molly Jones Molly Biggin Rebecca Legge Sadhbh Ni Chiobhain

We are pleased to have Spexis AG during our London lunch event. Spexis, a Swiss clinical-stage biopharmaceutical company, specializes in rare diseases and cancer. Its lead candidate, ColiFin®, an inhaled therapy for cystic fibrosis, is approved in Europe and advancing to global pivotal Phase 3 studies in early 2023. Leveraging over 25 years and $400 million of research, Spexis aims to deliver transformative therapies while seeking strategic partnerships for product development and market expansion. Additionally, it expands its portfolio through in-licensing or acquisitions, targeting areas with significant unmet medical needs. The Global Rare Disease Treatment Market size was valued at $152bn in 2023 and is poised to grow at a CAGR of 12.8% to reach $400bn by 2031. Our Family is looking closely at their strategy to take a view on this opportunity.   #UCEACapital #investing #familyoffices #London #SPEXIS #Healthcare #oncology #biotech 

🤝 Generate:Biomedicines & Novartis collaboration   A new, massive, #AI-based drug discovery deal was announced on September 24. Novartis and Generate:Biomedicines announced a multi-target collaboration to discover and develop protein therapeutics.   The deal leverages “The Generate Platform”, a proprietary genAI platform and combines it with Novartis capabilities to accelerate drug discovery and development. The scope of targets or therapeutic areas is not disclosed. However, as per the terms of the collaboration, Generate:Biomedicines will receive a total upfront payment of $65m. Total performance-based milestones are evaluated above $1Bn along with low double-digits royalties.   As of today, the AI-powered biotech has built a pipeline of more than 15 candidates in immunology, oncology, ADCs and infectious diseases with partners like Amgen, MD Anderson Cancer Center and Roswell Park Comprehensive Cancer Center.   🔭 On a larger trend, AI in early-stage drug development is here to stay, with drug development costs ranging from $2.8Bn to $6.1Bn per approval, quoting Andrii Buvailo, Ph.D. and Alex Zhavoronkov.   📌 As always, check out sources in first comment! #artificialintelligence #machinelearning #drugdiscovery

💉 𝗟𝗲𝘁’𝘀 𝗻𝗼𝘁 𝘀𝘁𝗿𝗮𝘆 𝘁𝗼𝗼 𝗳𝗮𝗿 𝗳𝗿𝗼𝗺 𝗞𝗲𝘆𝘁𝗿𝘂𝗱𝗮! 🧬 🟢 In the previous post, we discussed #Keytruda’s development history, its approved indications, and its increasing sales year by year after hitting the market. We also took a peek into Merck’s efforts to extend Keytruda’s exclusivity by filing numerous patents around this valuable blockbuster! 🟢 Pembrolizumab, the active ingredient in Keytruda, is a powerhouse in the PD-1 inhibitor class of cancer treatments. PD-1, or programmed cell death-1 receptor, is crucial to the body’s immune response. By blocking the interaction between PD-1 and its ligand PD-L1, pembrolizumab empowers the immune system to better recognize and destroy tumor cells. 🟢 With Keytruda’s patent expiration still four years away, biosimilar makers are gearing up for a major opportunity. Developing biosimilars can significantly benefit patients by providing more affordable treatment options, offering the same effectiveness as the original biologic drugs at a lower cost, thereby improving access to life-saving medications. 🟢 While it’s too early to predict who will bring the first pembrolizumab biosimilar to market, several major developers are making significant strides. Companies like Samsung Bioepis, Sandoz, Amgen, Bio-Thera Solutions, and mAbxience have promising candidates in the clinical trial studies, while Formycon AG, Alvotech, Henlius, and NeuClone have Keytruda's biosimilars on their preclinical pipeline. Moreover, Xbrane Biopharma AB had indicated an interest in its pembrolizumab biosimilar candidate but announced in November 2023 that it was terminating development. 🟢 𝗪𝗲 𝗦𝘁𝗮𝘆 𝗧𝘂𝗻𝗲𝗱 as these developments unfold, potentially reshaping cancer therapy with new and more affordable treatment options. The competition is heating up, and the outcome could transform the landscape of #oncology! #biosimilar #biopharma #pharmaceuticalindustry #blockbuster #clinicaltrial #pembrolizumab

#Smallmolecules represent the next frontier of immuno-oncology and such drugs now entering the clinical research stage. #Kumquat has been on the forefront with its first small-molecule #immunooncology partnership with #EliLilly in July 2021. Takeda's #oncologypipeline consists primarily of small molecules which means that there are several combination opportunities that could be explored with Kumquat`s molecule. Between Takeda and Eli Lilly, Kumquat stands to make ~$3.2B in future development, regulatory and commercial milestones. #innovation #oncology

💉 𝗟𝗲𝘁’𝘀 𝗻𝗼𝘁 𝘀𝘁𝗿𝗮𝘆 𝘁𝗼𝗼 𝗳𝗮𝗿 𝗳𝗿𝗼𝗺 𝗞𝗲𝘆𝘁𝗿𝘂𝗱𝗮! 🧬 🟢 In the previous post, we discussed #Keytruda’s development history, its approved indications, and its increasing sales year by year after hitting the market. We also took a peek into Merck’s efforts to extend Keytruda’s exclusivity by filing numerous patents around this valuable blockbuster! 🟢 Pembrolizumab, the active ingredient in Keytruda, is a powerhouse in the PD-1 inhibitor class of cancer treatments. PD-1, or programmed cell death-1 receptor, is crucial to the body’s immune response. By blocking the interaction between PD-1 and its ligand PD-L1, pembrolizumab empowers the immune system to better recognize and destroy tumor cells. 🟢 With Keytruda’s patent expiration still four years away, biosimilar makers are gearing up for a major opportunity. Developing biosimilars can significantly benefit patients by providing more affordable treatment options, offering the same effectiveness as the original biologic drugs at a lower cost, thereby improving access to life-saving medications. 🟢 While it’s too early to predict who will bring the first pembrolizumab biosimilar to market, several major developers are making significant strides. Companies like Samsung Bioepis, Sandoz, Amgen, Bio-Thera Solutions, and mAbxience have promising candidates in the clinical trial studies, while Formycon AG, Alvotech, Henlius, and NeuClone have Keytruda's biosimilars on their preclinical pipeline. Moreover, Xbrane Biopharma AB had indicated an interest in its pembrolizumab biosimilar candidate but announced in November 2023 that it was terminating development. 🟢 𝗪𝗲 𝗦𝘁𝗮𝘆 𝗧𝘂𝗻𝗲𝗱 as these developments unfold, potentially reshaping cancer therapy with new and more affordable treatment options. The competition is heating up, and the outcome could transform the landscape of #oncology! #biosimilar #biopharma #pharmaceuticalindustry #blockbuster #clinicaltrial #pembrolizumab